Across TCGA pan-cancer cohorts, OR52E6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR52E6 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher OR52E6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR52E6 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

PRAD, ACC, and SKCM are the cancer types where OR52E6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SKCM	OS	Median	III,IV	1.000	0.688	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: OR52E6 tumor-vs-normal RNA expression · all OR52E6 data types